Evolution of hepatitis B virus sequence from a liver transplant recipient with rapid breakthrough despite hepatitis B immune globulin prophylaxis and lamivudine therapy

Journal of Medical Virology

Volumn 71, Issue 3, 2003, Pages 367-375

  Kim, Kyun Hwan ^a,b   Lee, Kwang Hee ^a   Chang, Hye Young ^a,b   Ahn, Sang Hoon ^a,b   Tong, Shuping ^c   Yoon, Young Joon ^a   Seong, Baik L ^a   Kim, Soon Il ^a   Han, Kwang Hyub ^a,b,d  

^a Yonsei University   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c BROWN UNIVERSITY   (United States)

^d Yonsei University College of Medicine   (South Korea)

Author keywords

HBIG; HBV mutant; Lamivudine; Liver transplantation

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE;

ADULT; ANTIGEN BINDING; ARTICLE; CASE REPORT; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER TRANSPLANTATION; MALE; NONSENSE MUTATION; NUCLEOTIDE SEQUENCE; POINT MUTATION; REINFECTION; SEQUENCE ANALYSIS; VIRUS GENOME; VIRUS MUTATION;

BASE SEQUENCE; DRUG RESISTANCE, VIRAL; EVOLUTION, MOLECULAR; GENOME, VIRAL; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULINS; LAMIVUDINE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; SEQUENCE ANALYSIS, DNA;

HEPATITIS B VIRUS;

EID: 0141869935     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmv.10503     Document Type: Article

References (34)

1. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, Brown N, Condreay LD. 1998. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 27:1670-1677.
2. Ben-Ari Z, Shmueli D, Mor E, Shapira Z, Tur-Kaspa R. 1997. Beneficial effect of lamivudine in recurrent hepatitis B after liver transplantation. Transplantation 63:393-396.
3. Benhamou Y, Katlama C, Lunel F, Coutellier A, Dohin E, Hamm N, Tubiana R, Herson S, Poynard T, Opolon P. 1996. Effects of lamivudine on replication of hepatitis B virus in HIV-infected men. Ann Intern Med 125:705-712.
4. Bock CT, Tillmann HL, Torresi J, Klempnauer J, Locarnini S, Manns MP, Trautwein C. 2002. Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation. Gastroenterology 122:264-273.
5. Doong SL, Tsai CH, Schinazi RF, Liotta DC, Cheng YC. 1991. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′ -dideoxy-3′-thiacytidine and related analogues. Proc Natl Acad Sci USA 88:8495-8499.
6. Fu L, Cheng YC. 1998. Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance. Biochem Pharmacol 55:1567-1572.
7. Ghany MG, Ayola B, Villamil FG, Gish RG, Rojter S, Vierling JM, Lok AS. 1998. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology 27:213-322.
8. Grellier L, Mutimer D, Ahmed M, Brown D, Burroughs AK, Rolles K, McMaster P, Beranek P, Kennedy F, Kibbler H, McPhillips P, Elias E, Dusheiko G. 1996. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 348:1212-1215.
9. Gunther S, Li BC, Miska S, Kruger DH, Meisel H, Will H. 1995. A novel method for efficient amplification of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutants in immunosuppressed patients. J Virol 69:5437-5444.
10. Ijaz S, Torre F, Tedder RS, Williams R, Naoumov NV. 2001. Novel immunoassay for the detection of hepatitis B surface 'escape' mutants and its application in liver transplant recipients. J Med Virol 63:210-216.
11. Jeantet D, Chemin I, Mandrand B, Zoulim F, Trepo C, Kay A. 2002. Characterization of two hepatitis B virus populations isolated from a hepatitis B surface antigen-negative patient. Hepatology 35:1215-1224.
12. Kobayashi M, Koike K. 1984. Complete nucleotide sequence of hepatitis B virus DNA of subtype adr and its conserved gene organization. Gene 30:227-232.
13. Lin TS, Luo MZ, Liu MC, Pai SB, Dutschman GE, Cheng YC. 1994. Synthesis and biological evaluatien of 2′,3′-dideoxy-L-pyrimidine nucleosides as potential antiviral agents against human immunodeficiency virus (HIV) and hepatitis B virus (HBV). J Med Chem 37:798-803.
14. Lin X, Qian GS, Lu PX, Wu L, Wen YM. 2001. Full-length genomic analysis of hepatitis B virus isolates in a patient progressing from hepatitis to hepatocellular carcinoma. J Med Virol 64:299-304.
15. Liu CJ, Chen PJ, Lai MY, Kao JH, Chen DS. 2001. Hepatitis B virus variants in patients receiving lamivudine treatment with breakthrough hepatitis evaluated by serial viral loads and full-length viral sequences. Hepatology 34:583-589.
16. Markowitz JS, Martin P, Conrad AJ, Markmann JF, Seu P, Yersiz H, Goss JA, Schmidt P, Pakrasi A, Artinian L, Murray NG, Imagawa DK, Holt C, Goldstein LI, Stribling R, Busuttil RW. 1998. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 28:585-589.
17. Marzano A, Salizzoni M, Debernardi-Venon W, Smedile A, Franchello A, Ciancio A, Gentilcore E, Piantino P, Barbui AM, David E, Negro F, Rizzetto M. 2001. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol 34:903-910.
18. Mutimer D, Pillay D, Dragon E, Tang H, Ahmed M, O'Donnell K, Shaw J, Burroughs N, Rand D, Cane P, Martin B, Buchan S, Boxall E, Barmat S, Gutekunst K, McMaster P, Elias E. 1999. High pre-treatment serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation. J Hepatol 30:715-721.
19. Ogata N, Fujii K, Takigawa S, Nomoto M, Ichida T, Asakura H. 1999. Novel patterns of amino acid mutations in the hepatitis B virus polymerase in association with resistance to lamivudine therapy in Japanese patients with chronic hepatitis B. J Med Virol 59:270-276.
20. O'Grady JG, Smith HM, Davies SE, Daniels HM, Donaldson PT, Tan KC, Portmann B, Alexander GJ, Williams R. 1992. Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications. J Hepatol 14:104-111.
21. Ono-Nita SK, Kato N, Shiratori Y, Masaki T, Lan KH, Carrilho FJ, Omata M. 1999. YMDD motifin hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: a study by in vitro full-length viral DNA transfection. Hepatology 29:939-945.
22. Owiredu W-K, Kramvis A, Kew MC. 2001. Molecular analysis of hepatitis B virus genomes isolated from black African patients with fulminant hepatitis B. J Med Virol 65:485-492.
23. Paik YH, Chung HY, Ryu WS, Lee KS, Lee JS, Kim JH, Lee CK, Chon CY, Moon YM, Han KH. 2001. Emergence of YMDD motif mutant of hepatitis B virus during short-term lamivudine therapy in South Korea. J Hepatol 35:92-98.
24. Preikschat P, Gunther S, Reinhold S, Will H, Budde K, Neumayer HH, Kruger DH, Meisel H. 2002. Complex HBV populations with mutations in core promoter, C gene, and pre-S region are associated with development of cirrhosis in long-term renal transplant recipients. Hepatology 35:466-477.
25. Protzer-Knolle U, Naumann U, Bartenschlager R, Berg T, Hopf U, Meyer zum Buschenfelde KH, Neuhaus P, Gerken G. 1998. Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. Hepatology 27:254-263.
26. Rosenau J, Bahr MJ, Tillmann HL, Trautwein C, Klempnauer J, Manns MP, Boker KHW. 2001. Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection. J Hepatol 34:895-902.
27. Schories M, Peters T, Rasenack J. 2000. Isolation, characterization and biological significance of hepatitis B virus mutants from serum of a patient with immunologically negative HBV infection. J Hepatol 33:799-811.
28. Shouval D, Samuel D. 2000. Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: a concise review. Hepatology 32:1189-1195.
29. Terrault NA, Zhou S, McCory RW, Pruett TL, Lake JR, Roberts JP, Ascher NL, Wright TL. 1998. Incidence and clinical consequences of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin. Hepatology 28:555-561.
30. Tillmann HL, Trautwein C, Bock T, Boker KH, Jackel E, Glowienka M, Oldhafer K, Bruns I, Gauthier J, Condreay LD, Raab HR, Manns MP. 1999. Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIg immunoglobulin after liver transplantation. Hepatology 30:244-256.
31. Torresi J, Earnest-Silveira L, Civitico G, Walters TE, Lewin SR, Fyfe J, Locarnini SA, Manns M, Trautwein C, Bock TC. 2002a. Restoration of replication phenotype of lamivudine-resistant hepatitis B virus mutants by compensatory changes in the "fingers" subdomain of the viral polymerase selected as a consequence of mutations in the overlapping S gene. Virology 299:88-99.
32. Torresi J, Earnest-Silveira L, Deliyannis G, Edgtton K, Zhuang H, Locarnini SA, Fyfe J, Sozzi T, Jackson DC. 2002b. Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy. Virology 293:305-313.
33. Yeh CT, Chien RN, Chu CM, Liaw YF. 2000. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. Hepatology 31:1318-1326.
34. Yuen MF, Sablon E, Hui CK, Yuan HJ, Decraemer H, Lai CL. 2001. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 34:785-791.